Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes. - Wikidata - awgldk - TriplyDB

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.

http://www.wikidata.org/entity/Q31046934

about

Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease The Real-Life Effectiveness and Care Patterns of Diabetes Management Study for Balkan Region (Slovenia, Croatia, Serbia, Bulgaria): A Multicenter, Observational, Cross-Sectional Study.Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus.Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers Effectiveness of Automated Insulin Management Features of the MiniMed® 640G Sensor-Augmented Insulin Pump.Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.Economic impact of hypoglycemia among insulin-treated patients with diabetes.Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.The association of hypoglycaemia severity and clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin.Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review.Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.The burden of severe hypoglycemia in type 1 diabetes.The burden of severe hypoglycemia in type 2 diabetes.A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.Real-world crude incidence of hypoglycemia in adults with diabetes: Results of the InHypo-DM Study, Canada.DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study.A Minimal Model Approach for Analyzing Continuous Glucose Monitoring in Type 2 Diabetes.Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting

P2860

Q33834187-6C297D72-C146-497F-9911-517CA836B935 Q38684834-43F5114F-633E-4B4C-A902-EBAEB7299267 Q38833204-0FA671DC-E4F8-4BB9-82E0-60C8CD00296F Q39032289-939BACA6-FBCC-4CFF-9FE5-F10E9DBD1820 Q39249702-A2AABC71-FC60-4081-9A48-B5CBD9FFA238 Q39347625-292869FD-5C16-4C9E-89CC-656D303CCAF9 Q39462093-88CDA89E-1FEE-4CEE-AC48-306A24FE8004 Q40540436-4F960524-1B86-4953-B074-7333CA15AB20 Q42371337-DCFAC04A-983C-4B19-A324-7A64E3FC6A73 Q47188930-83E3B50F-F475-488E-83A7-F09CD1AEC1DF Q47654133-C02DEF5B-2367-4F62-94A9-4432C9DD6185 Q47871150-35418968-2775-49B4-9912-7A54DB349C86 Q48211822-2F33B590-6981-4402-85D1-04FF906E9DC9 Q48214880-D3BCD557-71BF-4A91-A402-11B11DF81F5D Q51244521-00780C0B-6418-47B0-BEF5-102BD57A1838 Q53827419-4AA270C6-0D63-47C7-BFA2-AA05433AA2EE Q55231953-F354C821-249D-43A8-8CBF-D387B3877CDD Q55339550-B71CBF73-4862-44D6-B544-9D03E0435B59 Q55343036-FDDF64F0-3F23-499A-ADAC-2B752140DC71 Q58788707-EA2DBBCA-7DE3-492C-87E6-016C66938D14

P2860

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.

http://www.wikidata.org/entity/Q31046934

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Hypoglycemia Event Rates: A Co ...... s in Insulin-Treated Diabetes.

@ast

Hypoglycemia Event Rates: A Co ...... s in Insulin-Treated Diabetes.

@en

type

label

Hypoglycemia Event Rates: A Co ...... s in Insulin-Treated Diabetes.

@ast

Hypoglycemia Event Rates: A Co ...... s in Insulin-Treated Diabetes.

@en

prefLabel

Hypoglycemia Event Rates: A Co ...... s in Insulin-Treated Diabetes.

@ast

Hypoglycemia Event Rates: A Co ...... s in Insulin-Treated Diabetes.

@en

P1433

Q31046934-D6D9D9C5-BEF6-4A9A-A67D-D12DD33EEB87

P1476

Q31046934-2E32252E-D298-4C02-8F55-1FFF8BE9A4D2

P2093

Q31046934-29A2E66C-914E-466E-967D-19E530CE33EA

Q31046934-3DB19ECF-0667-47DB-B425-99CC9AF9694C

Q31046934-A681AF86-4760-48E7-AF59-639C057F1ACA

Q31046934-BF39A501-B4C2-4CFD-9CCD-797ED83E3E60

P2860

Q31046934-0A0B6201-4C24-4561-92DF-166A53D6E3BE

Q31046934-14D10732-22FE-44FE-A69B-A214234BACD7

Q31046934-1BFAB235-B8F4-4567-A31D-C6C33D2CF87E

Q31046934-2073210C-FFCD-497E-B4D5-F050DD369B39

Q31046934-2B7B8CF1-410F-41F6-9DB5-4035F25DCA55

Q31046934-2FA9CB6E-5FD1-4008-B6B1-40C813592317

Q31046934-30C0BC07-3916-4B29-B96E-13A07C98D470

Q31046934-34B9F6E3-531E-414E-A092-ECB39C5409EA

Q31046934-38EBD43A-3570-4E20-AA49-F876060085F8

Q31046934-3CE1E671-5B2A-48FA-8E31-3CFF28CDF0B8

P2888

Q31046934-0EFF3166-C616-472B-B3D6-503608A1F596

P304

Q31046934-CFBB0307-DF4C-42E6-B47E-6ED0583D7D0A

P31

Q31046934-BFFB40CA-D583-4662-9A7C-4486599E477A

P356

Q31046934-56C60184-A986-44BD-9DD7-99D0676AAEA4

P433

Q31046934-3A96D25C-DE04-42F6-A8DE-B32A68D516B3

P478

Q31046934-FCDA8BC0-134D-49D8-BDD8-C10008A0DAA3

P577

Q31046934-FD947B6D-A06F-41D8-9666-C7D7A9F1EAF9

P5875

Q31046934-ED172F7F-C685-4807-BBD2-AA5C5A237DD2

P6179

Q31046934-1DE520D1-CEDB-4658-A9FF-B8380ED3FECC

P698

Q31046934-AD49A9A7-62BE-4961-94B3-E38F08CD1409

P921

Q31046934-5C66935A-66AA-421E-AEAA-D3767CA8F38D

Q31046934-C74535E2-DDED-4F71-97F8-A688A9DDC5E0

P932

Q31046934-70252346-4E11-40AF-8788-DA113DB5C960

P356

S13300-016-0157-Z

P1433

Diabetes Therapy

P1476

Hypoglycemia Event Rates: A Co ...... s in Insulin-Treated Diabetes.

@en

P2093

Andrea Ditchfield

http://www.w3.org/2001/XMLSchema#string

Carrie Fidler

http://www.w3.org/2001/XMLSchema#string

Lisa Elliott

http://www.w3.org/2001/XMLSchema#string

Trine Stissing

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Standards of medical care in diabetes--2014

Importance of observational studies in clinical practice.

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.

Impaired awareness of hypoglycaemia: a review.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

P2888

s13300-016-0157-z

P304

45-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-016-0157-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

294918516

http://www.w3.org/2001/XMLSchema#string

P6179

1038704969

http://www.w3.org/2001/XMLSchema#string

P698

26886441

http://www.w3.org/2001/XMLSchema#string

P921

P932

4801820

http://www.w3.org/2001/XMLSchema#string